Abbott agrees with Justice Department to resolve infant formula recall claims
Abbott has reached an agreement with the Department of Justice to resolve claims related to its 2022 infant formula recall. The settlement does not involve any finding of fault or liability.
Medical device manufacturer Abbott has reached an agreement with the U.S. Department of Justice to settle claims stemming from its 2022 infant formula recall. Specific terms of the settlement were not disclosed, but Abbott stated that it does not represent any finding of fault or liability.
The federal government had previously indicated that it had closed its criminal investigation into the matter. The 2022 recall, which primarily involved Abbott's Similac brand, was linked to bacterial infections in several infants, leading to a temporary plant shutdown and significant supply shortages in the U.S.
The incident sparked widespread scrutiny of food safety regulations and industry oversight. Abbott has since implemented enhancements to its manufacturing processes and safety protocols to ensure product safety.